Bristol-Myers Squibb and UCLA link up as part of US Immuno-Oncology Rare Population Malignancy programme

The two organisations will conduct a range of early phase clinical studies

Bristol-Myers Squibb is to collaborate with University of California Los Angeles (UCLA) as part of the firm’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research programme in the US.

Bristol-Myers Squibb and the David Geffen School of Medicine at UCLA will conduct a range of early phase clinical studies. In addition Bristol-Myers Squibb will fund positions within UCLA’s fellowship programme in the UCLA Division of Haematology/Oncology.

'The I-O RPM research programme is an important complement to Bristol-Myers Squibb’s broad research and development programme for immuno-oncology,' said Laura Bessen, Head of US Medical, Bristol-Myers Squibb. 'We look forward to working with UCLA in an effort to continue advancing the science in this innovative field of research and cancer treatment.'

The I-O RPM is a multi-institutional initiative with academic-based cancer centres focused on the clinical investigation of immuno-oncology therapeutics as potential treatments for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

Other partners include Robert H. Lurie Comprehensive Cancer Centre of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute, Moffitt Cancer Centre, The Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins and now UCLA.

Companies